Mats Wahlstrom - Aug 10, 2023 Form 3 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Role: Director, 10%+ Owner
Signature: /s/ Sean Murphy, Attorney-in-Fact for Mats Wahlstrom
Stock symbol: TLSI
Transactions as of: Aug 10, 2023
Transactions value $: $0
Form type: 3
Date filed: 8/14/2023, 06:13 PM
Previous filing: Jun 9, 2023
Next filing: Feb 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TLSI	Common Stock						1.25M	Aug 10, 2023	By Leonard Capital LLC	F1, F2
holding	TLSI	Common Stock						1.37M	Aug 10, 2023	By HW Investment Partners, LLC	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	7.42K	$2.03	Direct	F1, F4
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	2.47K	$1.22	Direct	F1, F5
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	4.94K	$1.22	Direct	F1, F6
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	2.47K	$1.22	Direct	F1, F7
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	10.2K	$0.41	Direct	F1, F8
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	8.94K	$0.41	Direct	F1, F8
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	3.95K	$0.41	Direct	F1, F9
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	9.08K	$2.43	Direct	F1, F10
holding	TLSI	Stock Option (right to buy)							Aug 10, 2023	Common Stock	86.5K	$2.43	Direct	F1, F11
holding	TLSI	Series A Convertible Preferred Stock							Aug 10, 2023	Common Stock	50K	$10.00	By Leonard Capital LLC	F2, F12

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported herein were acquired by the Reporting Person in connection with the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.). The Reporting Person was appointed as a director of the Issuer effective immediately after the effective time of the Merger.
F2	The Reporting Person shares voting and investment discretion with his spouse with respect to the shares held directly by Leonard Capital LLC.
F3	The Reporting Person is a managing member of HW Investment Partners, LLC ("HW Investment") and shares voting and investment discretion with respect to the shares held directly by HW Investment. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4	The shares subject to this stock option became fully vested on July 21, 2021.
F5	The shares subject to this stock option became fully vested on January 1, 2020.
F6	The shares subject to this stock option became fully vested on February 26, 2022.
F7	The shares subject to this stock option became fully vested on April 24, 2021.
F8	The shares subject to this stock option vest in 48 equal monthly installments from the vesting commencement date of April 22, 2020, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F9	The shares subject to this option shall vest in equal quarterly installments over three years, with 1/12th of the total number of shares subject to the option vesting on each quarterly anniversary of the vesting commencement date of January 1, 2021, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F10	The shares subject to this stock option vest in 48 equal monthly installments from the vesting commencement date of November 3, 2021, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F11	Twenty-five percent of the shares subject to the option vested on June 17, 2023, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F12	The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 50,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock will automatically convert into shares of the Issuer's Common Stock on August 10, 2027.